<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466452</url>
  </required_header>
  <id_info>
    <org_study_id>S181/211</org_study_id>
    <nct_id>NCT01466452</nct_id>
  </id_info>
  <brief_title>Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery</brief_title>
  <acronym>ASABYVALV</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catholic University, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized open label study that implies the administration of asprin
      according to three different regimens.

      The aims of the study are:

        -  to establish whether coronary artery bypass surgery and / or aortic valve replacement
           surgery with bioprostheses is associated with changes in the rate of platelet
           regeneration that can reduce the effectiveness of aspirin administered at a dose of
           100mg/die in terms of inhibition of platelet biosynthesis of thromboxane A2.

        -  to determine whether these patients need a different (shorter) interval of
           administration in order to completely and permanently inhibit the platelet COX-1.

      The endpoints of this study are:

      - To evaluate the changes in the levels of TXB2 and 12-HETE in serum at 12 and 24 hours after
      administration of aspirin and the changes in the levels of 11-dehydro TXB2 urinary 8-iso-PGF2
      alpha urinary, 2-3 dinor-6-chetoPGF1 alpha, Verify-NOW Aspirin, platelets crosslinked at 12
      and 24 hours after administration of aspirin
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the levels of TXB2 in serum at 12 and 24 hours after administration of aspirin</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in the levels of 12-HETE in serum at 12 and 24 hours after administration of aspirin</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the levels of 11-dehydro TXB2 urinary at 12 and 24 hours after administration of aspirin</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the levels of 8-iso-PGF2 alpha urinary at 12 and 24 hours after administration of aspirin</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the levels of 2-3 dinor-6-chetoPGF1 alpha at 12 and 24 hours after administration of aspirin</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the levels of Verify-NOW Aspirin, platelets crosslinked at 12 and 24 hours after administration of aspirin</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Aspirin 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 200</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 100 x 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>single-dose aspirin in 100 mg 1 tablet every 24 hours</description>
    <arm_group_label>Aspirin 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>single-dose aspirin 200 mg 1 tablet every 24 hours</description>
    <arm_group_label>Aspirin 200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>double-dose aspirin 100 mg 1 tablet every 12 hours</description>
    <arm_group_label>Aspirin 100 x 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent of the study signed

          -  coronary artery bypass graft and / or aortic valve replacement surgery with
             bioprostheses

          -  age between 55 and 80

          -  ejection fraction &gt; 30%.

        Exclusion Criteria:

          -  excessive bleeding (&gt; 1000mL / 6 h) or the need of re operation for bleeding

          -  perioperative myocardial infarction

          -  stroke or renal failure requiring dialysis and need waiting for post-operative
             anticoagulation

          -  patients undergoing coronary artery bypass grafting procedure as a consequence of
             failed percutaneous coronary intervention

          -  patients undergoing off-pump coronary artery bypass graft

          -  overt kidney or liver disease

          -  therapies that influence the coagulation

          -  fertile women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandro Parolari, MD PhD</last_name>
    <phone>+39 025800</phone>
    <phone_ext>2355</phone_ext>
    <email>alessandro.parolari@ccfm.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino, IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Parolari, MD PhD</last_name>
      <phone>+39 02 5800</phone>
      <phone_ext>2355</phone_ext>
      <email>alessandro.parolari@ccfm.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Parolari, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Alessandro Parolari</investigator_full_name>
    <investigator_title>Assistant Professor of Cardiac Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

